Center for Studies on New Religions’ Bitter Winter Publishes Statement by Religious Freedom and Human Rights Organizations On Japanese Government’s Undemocratic Request to Dissolve a Minority Religion
14 oct. 2023 10h33 HE
|
Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Oct. 14, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Center for Studies on New Religions’ Bitter WinterPublishes Statement by Religious Freedom and Human Rights...
Center for Studies on New Religions’ Bitter Winter Publishes Statement by Religious Freedom and Human Rights Organizations On Japanese Government’s Undemocratic Request to Dissolve a Minority Religion
14 oct. 2023 10h32 HE
|
Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Oct. 14, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Center for Studies on New Religions’ Bitter WinterPublishes Statement by Religious Freedom and Human Rights...
Center for Studies on New Religions’ Bitter Winter Publishes Statement by Religious Freedom and Human Rights Organizations On Japanese Government’s Undemocratic Request to Dissolve a Minority Religion
14 oct. 2023 05h41 HE
|
Center for Studies on New Religions, "Bitter Winter"
Washington, DC, Oct. 14, 2023 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Center for Studies on New Religions’ Bitter WinterPublishes Statement by Religious Freedom and Human Rights...
Japanese Rock Legend and Philanthropist YOSHIKI Named JAPAN HOUSE Los Angeles Advisor
01 août 2023 12h06 HE
|
JAPAN HOUSE Los Angeles
LOS ANGELES, Aug. 01, 2023 (GLOBE NEWSWIRE) -- JAPAN HOUSE Los Angeles – part of a worldwide project conceived by the Ministry of Foreign Affairs of Japan – proudly announces that world renowned...
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
03 sept. 2015 20h44 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
24 nov. 2013 19h16 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...